AR040221A1 - Compuesto de imidazol, metodo de preparacion y uso - Google Patents
Compuesto de imidazol, metodo de preparacion y usoInfo
- Publication number
- AR040221A1 AR040221A1 ARP030102114A ARP030102114A AR040221A1 AR 040221 A1 AR040221 A1 AR 040221A1 AR P030102114 A ARP030102114 A AR P030102114A AR P030102114 A ARP030102114 A AR P030102114A AR 040221 A1 AR040221 A1 AR 040221A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituents
- optionally
- divalent
- ring
- Prior art date
Links
- -1 IMIDAZOL COMPOUND Chemical class 0.000 title abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 14
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 241000590002 Helicobacter pylori Species 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000027119 gastric acid secretion Effects 0.000 abstract 1
- 229940037467 helicobacter pylori Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El compuesto exhibe una actividad antiúlcera, acción inhibitoria de la secreción de ácido gástrico, protección de mucosas, y acción anti Helicobacter pylori, etc. de carácter superior. Considerando que demuestra baja toxicidad, el compuesto resulta de utilidad como un producto farmacéutico. Reivindicación 1: Un compuesto de imidazol caracterizado por la fórmula (1), en la que: el anillo A es un anillo de piridina que opcionalmente posee sustituyentes; el anillo B es un anillo de benceno que opcionalmente posee sustituyentes o un heterociclo aromático monocíclico que opcionalmente posee sustituyentes, X1 y X2 son respectivamente un átomo de oxígeno o un átomo de azufre, W es un grupo hidrocarburo de cadena divalente que opcionalmente posee sustituyentes o un grupo divalente representado por la fórmula: -W1-Z-W2- donde W1 y W2 son respectivamente un grupo hidrocarburo de cadena divalente o un enlace, Z es un grupo de anillo hidrocarburo divalente que opcionalmente posee sustituyentes, un grupo heterocíclico divalente que opcionalmente posee sustituyentes, un átomo de oxígeno, Son donde n es 0, 1 o 2, o >N-E donde E es un átomo de hidrógeno, un grupo hidrocarburo que opcionalmente posee sustituyentes, un grupo heterocíclico que opcionalmente posee sustituyentes, un grupo alcanoilo inferior, un grupo alcoxicarbonilo inferior, un grupo aralquiloxicarbonilo, un grupo tiocarbamoilo, un grupo alquilsulfinilo inferior, un grupo alquilsulfonilo inferior, un grupo sulfamoilo, un grupo mono alquilsulfamoilo inferior, un grupo di-alquilsulfamoilo inferior, un grupo arilsulfamoilo, un grupo arilsulfinilo, un grupo arilsulfonilo, un grupo arilcarbonilo, o un grupo carbamoilo que opcionalmente posee sustituyentes, y cuando Z es un átomo de oxígeno, Son >N-E, W1 y W2 son respectivamente un grupo hidrocarburo de cadena divalente, R es un grupo hidrocarburo que opcionalmente posee sustituyentes o un grupo heterocíclico que opcionalmente posee sustituyentes, R y W pueden estar unidos entre sí, D1 y D2 son respectivamente un enlace, un átomo de oxígeno, un átomo de azufre o >NR1 donde R1 es un átomo de hidrógeno o un grupo hidrocarburo que opcionalmente posee sustituyentes, excepto cuando D1 y D2 son respectivamente un enlace, y Y es un grupo hidrocarburo que opcionalmente posee sustituyentes o un grupo heterocíclico que opcionalmente posee sustituyentes, o una sal del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002175086 | 2002-06-14 | ||
| JP2003041085 | 2003-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040221A1 true AR040221A1 (es) | 2005-03-16 |
Family
ID=29738411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102114A AR040221A1 (es) | 2002-06-14 | 2003-06-13 | Compuesto de imidazol, metodo de preparacion y uso |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060293371A1 (es) |
| EP (2) | EP1514870A4 (es) |
| JP (1) | JPWO2003106429A1 (es) |
| KR (1) | KR20050009751A (es) |
| CN (1) | CN1678315A (es) |
| AR (1) | AR040221A1 (es) |
| AT (1) | ATE437642T1 (es) |
| AU (2) | AU2003242390A1 (es) |
| BR (1) | BR0311801A (es) |
| CA (2) | CA2489361A1 (es) |
| DE (1) | DE60328603D1 (es) |
| IL (1) | IL165562A0 (es) |
| MX (1) | MXPA04012396A (es) |
| NO (1) | NO20050141L (es) |
| OA (1) | OA12867A (es) |
| PE (1) | PE20040563A1 (es) |
| PL (1) | PL373085A1 (es) |
| TW (1) | TW200307544A (es) |
| WO (2) | WO2003106429A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1740571E (pt) | 2004-04-28 | 2009-09-02 | Hetero Drugs Ltd | Processo para preparar compostos de piridinilmetil-1hbenzimidazol na forma enantiomericamente enriquecida ou como enantiómeros únicos |
| EP1852100B1 (en) | 2005-02-25 | 2018-05-09 | Takeda Pharmaceutical Company Limited | Method for producing coated granules of a benzimidazole compound |
| KR101148399B1 (ko) * | 2005-06-22 | 2012-05-23 | 일양약품주식회사 | 항궤양제 및 점막보호제를 함유하는 경구용 위장질환치료용 약제 조성물 |
| US20100317689A1 (en) * | 2006-09-19 | 2010-12-16 | Garst Michael E | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
| WO2008057802A2 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
| CA2716367C (en) | 2008-02-20 | 2015-05-26 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
| WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| WO2016172436A1 (en) * | 2015-04-23 | 2016-10-27 | Temple University-Of The Commonwealth System Of Higher Education | Polycationic amphiphiles and polymers thereof as antimicrobial agents and methods using same |
| EP3352754B1 (en) * | 2016-06-21 | 2020-09-02 | The Trustees of Columbia University in the City of New York | Aldose reductase inhibitors and methods of use thereof |
| WO2018081347A1 (en) | 2016-10-26 | 2018-05-03 | Temple University-Of The Commonwealth System Of Higher Education | Polycationic amphiphiles as antimicrobial agents and methods using same |
| IL272246B2 (en) | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| KR20220003529A (ko) | 2019-04-01 | 2022-01-10 | 어플라이드 테라퓨틱스 인크. | 알도스 리덕타제의 억제제 |
| MX2021013511A (es) | 2019-05-07 | 2022-02-23 | Univ Miami | Tratamiento y deteccion de neuropatias heredadas y trastornos asociados. |
| AU2021293694B2 (en) * | 2020-06-17 | 2023-12-21 | Ildong Pharmaceutical Co., Ltd. | Novel Acid Secretion Inhibitor and use thereof |
| IT202200001022A1 (it) * | 2022-01-21 | 2023-07-21 | Exo Lab Italia | Composti farmaceutici ibridi ottenuti mediante coniugazione di un inibitore delle pompe protoniche e un inibitore delle anidrasi carboniche |
| CN120590773B (zh) * | 2025-08-06 | 2025-12-26 | 广州仕天材料科技有限公司 | 一种增强型聚碳酸酯和制备方法及在汽车照明系统中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416649B (sv) * | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
| KR890000387B1 (ko) * | 1984-09-24 | 1989-03-16 | 디 엎존 캄파니 | 2-(피리딜알켄술 피닐)벤즈 이미드아졸류의 n-치환 유도체의 제조방법 |
| IL76839A (en) * | 1984-10-31 | 1988-08-31 | Byk Gulden Lomberg Chem Fab | Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
| SE8505112D0 (sv) * | 1985-10-29 | 1985-10-29 | Haessle Ab | Novel pharmacological compounds |
| US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
| US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US6093734A (en) * | 1998-08-10 | 2000-07-25 | Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin | Prodrugs of proton pump inhibitors |
| HUP0202431A3 (en) * | 1999-04-09 | 2003-03-28 | Basf Ag | Prodrugs of thrombin inhibitors |
| US6765019B1 (en) * | 1999-05-06 | 2004-07-20 | University Of Kentucky Research Foundation | Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| EP1790344B1 (en) * | 2000-07-07 | 2011-02-23 | Spectrum Pharmaceuticals, Inc. | Methods for treatment of disease-induced peripheral neuropathy and related conditions |
| WO2002030920A1 (en) | 2000-10-12 | 2002-04-18 | Takeda Chemical Industries, Ltd. | Benzimidazole compounds, process for producing the same and use thereof |
| US7129261B2 (en) * | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| US20040248941A1 (en) | 2001-09-25 | 2004-12-09 | Keiji Kamiyama | Benzimidazone compound, process for producing the same, and use thereof |
-
2003
- 2003-06-13 WO PCT/JP2003/007545 patent/WO2003106429A1/ja not_active Ceased
- 2003-06-13 AT AT03733426T patent/ATE437642T1/de not_active IP Right Cessation
- 2003-06-13 CA CA002489361A patent/CA2489361A1/en not_active Abandoned
- 2003-06-13 EP EP03733425A patent/EP1514870A4/en not_active Withdrawn
- 2003-06-13 PE PE2003000593A patent/PE20040563A1/es not_active Application Discontinuation
- 2003-06-13 PL PL03373085A patent/PL373085A1/xx not_active Application Discontinuation
- 2003-06-13 US US10/517,847 patent/US20060293371A1/en not_active Abandoned
- 2003-06-13 AU AU2003242390A patent/AU2003242390A1/en not_active Abandoned
- 2003-06-13 US US10/517,633 patent/US7410981B2/en not_active Expired - Fee Related
- 2003-06-13 MX MXPA04012396A patent/MXPA04012396A/es not_active Application Discontinuation
- 2003-06-13 WO PCT/JP2003/007546 patent/WO2003105845A1/en not_active Ceased
- 2003-06-13 DE DE60328603T patent/DE60328603D1/de not_active Expired - Lifetime
- 2003-06-13 CA CA002489470A patent/CA2489470A1/en not_active Abandoned
- 2003-06-13 EP EP03733426A patent/EP1513527B1/en not_active Expired - Lifetime
- 2003-06-13 AR ARP030102114A patent/AR040221A1/es not_active Application Discontinuation
- 2003-06-13 BR BR0311801-0A patent/BR0311801A/pt not_active IP Right Cessation
- 2003-06-13 AU AU2003242388A patent/AU2003242388A1/en not_active Abandoned
- 2003-06-13 KR KR10-2004-7020371A patent/KR20050009751A/ko not_active Withdrawn
- 2003-06-13 TW TW092116056A patent/TW200307544A/zh unknown
- 2003-06-13 OA OA1200400327A patent/OA12867A/en unknown
- 2003-06-13 JP JP2004513262A patent/JPWO2003106429A1/ja active Pending
- 2003-06-13 CN CNA038188953A patent/CN1678315A/zh active Pending
-
2004
- 2004-12-05 IL IL16556204A patent/IL165562A0/xx unknown
-
2005
- 2005-01-11 NO NO20050141A patent/NO20050141L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL165562A0 (en) | 2006-01-15 |
| TW200307544A (en) | 2003-12-16 |
| AU2003242388A1 (en) | 2003-12-31 |
| WO2003106429A1 (ja) | 2003-12-24 |
| OA12867A (en) | 2006-09-15 |
| JPWO2003106429A1 (ja) | 2005-10-13 |
| PE20040563A1 (es) | 2004-10-21 |
| EP1514870A1 (en) | 2005-03-16 |
| CA2489470A1 (en) | 2003-12-24 |
| WO2003105845A1 (en) | 2003-12-24 |
| EP1514870A4 (en) | 2006-08-23 |
| MXPA04012396A (es) | 2005-06-17 |
| US20050222210A1 (en) | 2005-10-06 |
| US20060293371A1 (en) | 2006-12-28 |
| EP1513527B1 (en) | 2009-07-29 |
| ATE437642T1 (de) | 2009-08-15 |
| NO20050141L (no) | 2005-01-27 |
| NO20050141D0 (no) | 2005-01-11 |
| EP1513527A1 (en) | 2005-03-16 |
| DE60328603D1 (de) | 2009-09-10 |
| PL373085A1 (en) | 2005-08-08 |
| CA2489361A1 (en) | 2003-12-24 |
| AU2003242390A1 (en) | 2003-12-31 |
| BR0311801A (pt) | 2005-04-12 |
| US7410981B2 (en) | 2008-08-12 |
| CN1678315A (zh) | 2005-10-05 |
| KR20050009751A (ko) | 2005-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040221A1 (es) | Compuesto de imidazol, metodo de preparacion y uso | |
| AR101816A1 (es) | Derivados de 3-[(pirazol-5-il)-heteroaril]-benzamidas como agentes pesticidas | |
| MX2025004220A (es) | Compuestos triciclicos y sus usos | |
| BR9917518B1 (pt) | processos para a preparação de pesticidas 1-arilpirazóis e seus intermediários. | |
| PE20060361A1 (es) | Compuestos heterociclicos como inhibidores de la cinesina mitotica | |
| ECSP056016A (es) | Nuevos derivados de 2-piridinacarboxamida | |
| MEP40908A (en) | Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof | |
| ATE554065T1 (de) | Sulfoniumsalz-fotoinitiatoren | |
| UY28121A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos | |
| BRPI0516911A (pt) | método para a preparação de um composto e composto de anilina | |
| WO2004037811A8 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
| BR0009952A (pt) | Composto, pró-droga, processo para produzir um composto, composição farmacêutica, método para antagonizar um receptor de adenosina a3, para inibir a p38 map quinase e a produção de tnf-alfa e para prevenir ou tratar doenças, e uso de um composto | |
| MY140638A (en) | New heterocyclic compounds, which are active as inhibitors of beta-lactamases | |
| NO20060219L (no) | Forbindelser | |
| EP1535915A4 (en) | FURANOIC OR THIOPHENE DERIVATIVES AND THEIR MEDICAL USE | |
| CO6210825A2 (es) | Derivado de heterocicliden-n-(aril)acetamina | |
| NZ589748A (en) | Sunfonyl-substituted bicyclic compounds as modulators of PPAR | |
| DK2368887T3 (da) | 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer | |
| WO2005103037A3 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
| CO5640098A2 (es) | Acidos biariloximetilaren-carboxilicos | |
| AR100817A1 (es) | Pirazoles y tetrazoles sustituidos con halógeno | |
| AR074619A1 (es) | Derivados de ciclopentilacrilamida | |
| ECSP045234A (es) | PROCEDIMIENTO PARA LA FABRICACION DE DERIVADOS DE ACIDO MEVALONICO INHIBIDORES DE ß-HIDROXI-ß-METILGLUTARILO-CO-ENZIMA-A REDUCTASA | |
| ES2291722T3 (es) | Aminoalcoxiindoles como ligandos 5-ht6-receptores para el tratamiento de transtornos del snc. | |
| MX393004B (es) | Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |